A pilot study of an organised population‐based testing programme for prostate cancer
(2024) In BJU International 133(1). p.87-95- Abstract
- Objective
To determine the feasibility of a digitally automated population-based programme for organised prostate cancer testing (OPT) in Southern Sweden.
Patients and Methods
A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years (y). Risk stratification was based on PSA, PSA density (PSAD), and biparametric prostate MRI. Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA (≥ 3 ng/mL) had a urological check-up, including a DRE and TRUS. Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (prostate imaging reporting and data system [PI-RADS] 4–5) and/or... (More) - Objective
To determine the feasibility of a digitally automated population-based programme for organised prostate cancer testing (OPT) in Southern Sweden.
Patients and Methods
A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years (y). Risk stratification was based on PSA, PSA density (PSAD), and biparametric prostate MRI. Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA (≥ 3 ng/mL) had a urological check-up, including a DRE and TRUS. Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (prostate imaging reporting and data system [PI-RADS] 4–5) and/or PSAD > 0.15 ng/mL/cm3. Additional indications for prostate biopsies were palpable tumours, PSA ratio
Results
A total of 418 men had a PSA test (42%), with increasing participation rates by age (50y, 38%; 56y, 44%; and 62y, 45%). Among these, 35 men (8%) had elevated PSA (≥ 3 ng/mL: 50y, 1/139; 56y, 10/143; and 62y, 24/146). On MRI, 16 men (48%) had a negative scan (PI-RADS 0.15 ng/mL/cm3 or a suspicious finding on TRUS. Prostate cancer was diagnosed in ten men. Six men underwent active treatment, whereas four men were assigned to active surveillance.
Conclusion
Our OPT model is feasible from an operational point of view, but due to the limited scale of this study no conclusions can be made regarding the efficacy of the diagnostic model or outcome (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b5c58ce1-c28b-4652-92cd-bb9966172310
- author
- Alterbeck, Max
LU
; Thimansson, Erik
LU
; Bengtsson, Johan
LU
; Baubeta, Erik LU
; Zackrisson, Sophia LU ; Bolejko, Anetta LU
; Sandeman, Kevin LU ; Carlsson, Sigrid LU ; Jiborn, Thomas LU and Bjartell, Anders LU
- organization
- publishing date
- 2024
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BJU International
- volume
- 133
- issue
- 1
- pages
- 87 - 95
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:37523331
- scopus:85167566936
- ISSN
- 1464-4096
- DOI
- 10.1111/bju.16143
- language
- English
- LU publication?
- yes
- id
- b5c58ce1-c28b-4652-92cd-bb9966172310
- date added to LUP
- 2023-08-03 09:20:19
- date last changed
- 2025-02-04 15:56:48
@article{b5c58ce1-c28b-4652-92cd-bb9966172310, abstract = {{Objective<br/>To determine the feasibility of a digitally automated population-based programme for organised prostate cancer testing (OPT) in Southern Sweden.<br/><br/>Patients and Methods<br/>A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years (y). Risk stratification was based on PSA, PSA density (PSAD), and biparametric prostate MRI. Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA (≥ 3 ng/mL) had a urological check-up, including a DRE and TRUS. Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (prostate imaging reporting and data system [PI-RADS] 4–5) and/or PSAD > 0.15 ng/mL/cm3. Additional indications for prostate biopsies were palpable tumours, PSA ratio <br/>Results<br/>A total of 418 men had a PSA test (42%), with increasing participation rates by age (50y, 38%; 56y, 44%; and 62y, 45%). Among these, 35 men (8%) had elevated PSA (≥ 3 ng/mL: 50y, 1/139; 56y, 10/143; and 62y, 24/146). On MRI, 16 men (48%) had a negative scan (PI-RADS 0.15 ng/mL/cm3 or a suspicious finding on TRUS. Prostate cancer was diagnosed in ten men. Six men underwent active treatment, whereas four men were assigned to active surveillance.<br/><br/>Conclusion<br/>Our OPT model is feasible from an operational point of view, but due to the limited scale of this study no conclusions can be made regarding the efficacy of the diagnostic model or outcome}}, author = {{Alterbeck, Max and Thimansson, Erik and Bengtsson, Johan and Baubeta, Erik and Zackrisson, Sophia and Bolejko, Anetta and Sandeman, Kevin and Carlsson, Sigrid and Jiborn, Thomas and Bjartell, Anders}}, issn = {{1464-4096}}, language = {{eng}}, number = {{1}}, pages = {{87--95}}, publisher = {{Wiley-Blackwell}}, series = {{BJU International}}, title = {{A pilot study of an organised population‐based testing programme for prostate cancer}}, url = {{http://dx.doi.org/10.1111/bju.16143}}, doi = {{10.1111/bju.16143}}, volume = {{133}}, year = {{2024}}, }